Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND): a global, phase 3, randomised controlled trial
Laurie H. Sehn, Kai Hübel, Stefano Luminari, Christian Schölz, Antonio Salar, Shankara Paneesha, Björn Engelbrekt Wahlin, Panayiotis Panayiotidis, Hui‐Peng Lee, Ana Jiménez Ubieto, Juan‐Manuel Sancho, Tae‐Min Kim, Eva Domingo‐Doménech, Takahiro Kumode, Christina Poh, Catherine Thiéblemont, Dries Deeren, Edwin de Wit, Michael Arbushites, Irene Vassallo, Marek Trněný, Björn Engelbrekt Wahlin, Tae Min Kim, Eva Domingo‐Doménech
Topics & Concepts
MedicineRituximabFollicular lymphomaInternal medicineRefractory (planetary science)Randomized controlled trialOncologyFollicular phaseLymphomaPhases of clinical researchClinical trialStandard of careAggressive lymphomaChemotherapyLymphoma Diagnosis and TreatmentViral-associated cancers and disordersCutaneous lymphoproliferative disorders research